Expanded indiction allows earlier radioligand therapy in PSMA-positive metastatic hormane-sensitive prostate cancer based on phase 3 PSMAddition trial data.

Lead author Dr. Joan Carles and a team at Vall d’Hebron University Hospital, in Barcelona evaluated patients whose cancer had ...

"This approval signals a new era in the treatment of prostate cancer, representing a shift toward more targeted, early intervention," said Prostate Cancer Foundation Chief Executive Gina Carithers.

The FDA has expanded Pluvicto’s approval, allowing its use earlier in treatment for PSMA‑positive metastatic ...

Talazoparib plus enzalutamide met the primary endpoint in TALAPRO-2, lowering radiographic progression or death risk by 37% versus enzalutamide, with median rPFS not reached. Efficacy signals extended ...

FDA authorization moves ^177Lu-PSMA radioligand therapy into the metastatic hormone-sensitive setting for PSMA-positive disease, paired with an ARPI such as abiraterone, apalutamide, enzalutamide, or ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated ...

Novartis received FDA approval for Pluvicto in PSMA positive metastatic hormone sensitive prostate cancer. The decision ...

Prostate cancer is one of the most frequently diagnosed cancers in men yet is often highly treatable when detected early. It originates in the prostate gland, located between the bladder and the penis ...